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Abstract Alzheimer’s disease (AD) is an age-related
disorder that causes a loss of brain function. Hyperphos-
phorylation of tau and the subsequent formation of intra-
cellular neurofibrillary tangles (NFTs) are implicated in the
pathogenesis of AD. Hyperphosphorylated tau accumulates
into insoluble paired helical filaments that aggregate into
NFTs; therefore, regulation of tau phosphorylation repre-
sents an important treatment approach for AD. Heat shock
protein 27 (Hsp27) plays a specific role in human neu-
rodegenerative diseases; however, few studies have ex-
amined its therapeutic effect. In this study, we induced tau
hyperphosphorylation using okadaic acid, which is a pro-
tein phosphatase inhibitor, and generated a fusion protein
of Hsp27 and the protein transduction domain of the HIV
Tat protein (Tat-Hsp27) to enhance the delivery of Hsp27.
We treated Tat-Hsp27 to SH-SY5Y neuroblastoma cells for
2 h; the transduction level was proportional to the Tat-
hsp27 concentration. Additionally, Tat-Hsp27 reduced the
level of hyperphosphorylated tau and protected cells from
apoptotic cell death caused by abnormal tau aggregates.
These results reveal that Hsp27 represents a valuable pro-
tein therapeutic for AD.
Keywords Tau protein  Hyperphosphoylation 
Alzheimer’s disease  Heat shock protein 27  Protein
transduction domain
Introduction
Alzheimer’s disease (AD) is a progressive neurological
disorder that causes memory loss. Various pathological
hallmarks of AD include synaptic and neuronal loss, amyloid
plaques primarily composed of the 42-residue hydrophobic
b-amyloid peptide (Ab) (Selkoe 2002), and neurofibrillary
tangles (NFTs) composed of aggregates of hyperphospho-
rylated tau, which is a microtubule-associated protein (Kosik
and Shimura 2005). Amyloid plaques and NFTs are con-
sidered as the primary factors involved in the pathogenesis of
AD (Medeiros et al. 2010). Although previous studies have
primarily focused on the role of b-amyloid peptides, recent
studies on the role of tau in AD pathogenesis have indicated
that hyperphosphorylated tau aggregates into insoluble
paired helical filaments (PHFs), which induce neuronal
dysfunction (Santa-Maria et al. 2012). Moreover, these two
pathological hallmarks demonstrate synergistic effects on
synaptic dysfunction (Crimins et al. 2013; Chabrier et al.
2014).
As a microtubule-associated protein, aggregates of
normal tau protect cells against toxic hyperphosphoryla-
tion, although neuronal death occurred following a period
of survival (Hernandez and Avila 2007). However, tau is
not only abnormally phosphorylated but also aggregates
into insoluble forms such as PHFs and NFTs (Andorfer
et al. 2003; Citron 2010) in various AD mouse models
(Go¨tz et al. 2001; Denk and RichardWade-Martins 2009;
Baglietto-Vargas et al. 2014). Therefore, an approach that
reduces the level of hyperphosphorylated tau would
Sunghyun Choi and Jae Hoon Oh contributed equally to this work.
Electronic supplementary material The online version of this
article (doi:10.1007/s10571-015-0199-1) contains supplementary
material, which is available to authorized users.
& Jong-Sang Park
pfjspark@snu.ac.kr
1 Department of Chemistry, Seoul National University, 599
Gwanak-ro, Gwanak-gu, Seoul 151-747, Republic of Korea
123
Cell Mol Neurobiol (2015) 35:1049–1059
DOI 10.1007/s10571-015-0199-1
represent a valuable treatment for AD (Bue´e et al. 2000).
Tau can bind heat shock proteins (HSPs), which trigger
the recruitment of CHIP (which is a co-chaperone that
exhibits E3 activity), to the complex. CHIP has been
shown to interact with tau, appears to work in concert
with both Hsp70 and Hsp90 in degrading toxic tau species
(Saidi et al. 2015). CHIP induces the ubiquitination of tau
and activates its degradation when tau is defective
(Salminen et al. 2011). In addition, The BAG2/Hsp70
complex is tethered to the microtubule and this complex
can capture and deliver Tau to the proteasome for ubiq-
uitin-independent degradation (Carrettiro et al. 2009).
Curcumin also downregulated the levels of phosphory-
lated tau, which may be potentially attributed to the
curcumin-induced upregulation in BAG2 levels in the
neurons (Patil et al. 2013). Hsp27 directly associates with
hyperphosphorylated tau or PHFs and regulates cell sur-
vival by eliminating tau aggregates (Shimura et al.
2004b).
Heat shock proteins are induced in response to cellular
stress as molecular chaperones that inhibit protein aggre-
gation (Read and Gorman 2009). HSPs can prevent apop-
tosis and increase cell viability during cellular stress
(Shimura et al. 2004a; Kwon et al. 2007). HSPs are also
critical regulators of normal neural physiological function
and cell stress responses (Stetler et al. 2010; Arrigo 2013;
Song et al. 2014). However, the therapeutic effects of ex-
ogenous Hsp27 on disease models have not been investi-
gated. Therefore, in this study, we investigated whether
Hsp27 could reduce hyperphosphorylated tau in AD-in-
duced SH-SY5Y cells.
To more effectively deliver Hsp27 into cells, we com-
bined the HIV protein transduction domain (PTD) Tat with
the Hsp27 protein (Tat-Hsp27). HIV Tat (11 residues,
YGRKKRRQRRR) can rapidly transduce into cells
(Becker-Hapak et al. 2001) and deliver full-length proteins
into cells (Green et al. 2003). Tat-Hsp27 effectively re-
duced the phosphorylation of tau and rescued the cell death
caused by abnormal tau aggregates. Therefore, our study
suggests that Tat-Hsp27 may represent a potential protein
therapeutic for tau-induced neurodegeneration.
Materials and Methods
Construction of the Expression Vector
We designed a bacterial expression vector (His6-Tat-
Hsp27) containing hexahistidine leader sequence,
11-amino acid Tat PTD sequence (YGRKKRRQRRR), and
Hsp27 protein sequence. The Hsp27 fragment (BD Bio-
science) was generated by PCR using human cDNA as a
template and oligonucleotide primers containing BamHI
and XhoI restriction sites. The pET-28a vector (Novagen)
and the Tat PTD were digested with NdeI and BamHI and
ligated. The ligated vector was transformed into chemically
competent DH5a E. coli cells (Enzynomics, Korea). After
purification of the plasmid containing the Tat PTD, the
plasmid and the Hsp27 fragment were digested with
BamHI and XhoI and ligated. We also designed pET28a
vector containing Hsp27 (wt-Hsp27) genetically fused with
a hexahistidine (His6) tag. The plasmid was constructed by
digesting the pET28a vector with BamHI and XhoI re-
striction endonucleases and ligating the Hsp27 fragment
digested with the same restriction enzymes into the cut
vector. The recombinant plasmids (pET28a-Tat-Hsp27,
pET28a-Hsp27) were transformed into the Escherichia coli
strain BL21 (DE3) for protein expression (Enzynomics,
Korea).
Expression and Purification of Hsp27
The recombinant plasmid (His6-Tat-Hsp27) was trans-
formed into the E. coli strain BL21(DE3) for protein
expression. Transformed cells were plated on an LB agar
(Merck) plate containing kanamycin (Sigma-Aldrich) and
incubated overnight at 37 C. Two-hundred milliliters of
LB medium containing 1 mM kanamycin was inoculated
with a single colony and incubated overnight at 37 C
with shaking at 200 rpm. The following day, 1 L of LB
medium was inoculated with this preculture and incubated
at 37 C until an OD600 of 0.5 was reached. Protein ex-
pression was induced by the addition of Isopropyl b-D-1-
thiogalactopyranoside (MB cell, Korea) at a final con-
centration of 1 mM, and the cells were incubated at 37 C
for an additional 4 h. The cells were centrifuged at
6000 rpm for 15 min at 4 C and resuspended in binding
buffer (20 mM Tris–HCl, 500 mM NaCl, 35 mM imida-
zole, pH 7.5). Cells were lysed by sonication on ice using
a sonicator (Sonics Vibra-Cell VCX 750, Sonic & Ma-
terials Inc., USA) with 1-s pulses and 8-s pauses for
30 min. After sonication, the lysates were centrifuged at
10,000 rpm for 15 min. The clarified lysate was loaded
onto a pre-equilibrated HisTrap HP column (GE Health-
care). His-tagged Tat-Hsp27 protein was eluted with
elution buffer (20 mM Tris–HCl, 500 mM NaCl, 1 M
imidazole, pH 7.5). His-tagged Tat-Hsp27 was further
purified using size exclusion chromatography on a
HiLoad 16/600 Superdex 200 prep grade column (GE
Healthcare) using 20 mM Tris–HCl (pH 7.5) and 100 mM
NaCl. Wt-Hsp27 purification was performed in the same
manner as in the purification step above. For the detection
of Tat-Hsp27 delivery into cells, we conjugated FITC to
Tat-Hsp27 using an FITC labeling kit (Thermo Scientific).
The concentration of protein was determined using BCA
protein assay kit (Pierce).
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Labeling of wt-Hsp27, TAT-Hsp27
To eliminate any primary amines or ammonium ions from
previous buffer, the buffers for both wt-Hsp27 and TAT-
Hsp27 were exchanged with 50 mM sodium borate of pH
8.5 using Amicon ultra centrifugal filters. Two-hundred
thirty micrograms of the prepared protein was added to a
vial of FITC Reagent (50 lg). The reaction mixture was
incubated for 60 min at room temperature protected from
light. After adding the mixtures to the spin columns, they
were centrifuged to remove any excess FITC at 10009g for
1 min.
Cell Culture
SH-SY5Y human neuroblastoma cells were grown in
Roswell Park Memorial Institute 1640 medium supple-
mented with 10 % fetal bovine serum and 1 % antibiotic–
antimycotic under an atmosphere of 5 % CO2 and 95 % air
(all from WELGENE). The medium was refreshed every
three days. Cells below passage 24 were used for ex-
periments. We chose the SH-SY5Y cell line because these
human neuroblastoma cells express constantly endogenous
tau.
Western Blot Analysis
For Western blot analysis, the cells treated with Tat-Hsp27
and okadaic acid were washed in DPBS and harvested in
RIPA buffer (Pierce). To prevent from further phosphory-
lation, we added Protease inhibitor cocktail and
phosphatase inhibitor cocktail composed of sodium ortho-
vanadate, sodium molybdate, sodium tartrate, and imida-
zole (both from Sigma-Aldrich) into the cell lysates.
Lysates were then centrifuged at 15,0009g for 15 min at
4 C. The supernatant was separated in a 12 % SDS-PAGE
gel, and the proteins were transferred to a nitrocellulose
membrane. After blocking in 5 % skim milk/TBST (Tris-
buffered saline and 0.1 % Tween 20, pH 7.5), the mem-
brane was washed in TBST three times (15 min each) and
incubated with primary antibody overnight at 4 C. The
membrane was subsequently washed and incubated with the
appropriate secondary antibody (HRP-conjugated goat anti-
mouse and goat anti-rabbit) for 2 h at room temperature.
Protein signals were developed with ECL Western Blotting
Detection Reagent (Amersham Pharmacia Biotech, Piscat-
away, NJ, USA) exposed to X-ray film. Band intensities
were calculated with the Image J software, and the protein
band of interest was normalized to b-actin. Then, tau hy-
perphosphorylation was normalized to the total tau as a
ratio, pTau/Total tau. Peroxidase-linked anti-rabbit and
anti-mouse IgGs were purchased from Santa Cruz
Biotechnology (USA). Rabbit polyclonal anti-tau
phosphoserine 199/202 antibody and mouse monoclonal
anti-tau-1 antibody were obtained from Millipore (USA).
Anti-human total tau monoclonal antibody (HT 7), rabbit
anti-Hsp27 polyclonal antibody, and anti Phospho-PHF-tau
(detected phospho-S202, -T205) monoclonal antibody (AT
8) were purchased from Pierce Biotechnology (USA). Anti-
HIV1 tat monoclonal antibody was purchased from Abcam
(USA). Synthesized tat peptides (YGRKKRRQRRR) were
purchased from PEPTRON (Korea).
Immunocytochemistry
The SH-SY5Y cells were seeded on 2-well slides (Lab-Tek
chamber, Nalge Nunc, NY) at a density of 5.0 9 105 per
well, treated with 2 lM Tat-Hsp27 for 2 h, and then treated
with 10 nM okadaic acid for 14 h. The cells were rinsed
two times with PBS and fixed with 4 % paraformaldehyde
for 30 min. The cells were subsequently permeabilized for
10 min with 0.5 % Triton X-100 followed by three 5-min
washes in PBS. To reduce nonspecific binding, we used
PBS containing 0.5 % bovine serum albumin as blocking
buffer. After incubation with the blocking buffer for 1 h,
the cells were incubated with the primary antibody AT8
(anti Phospho-PHF-tau detected phospho-S202, -T205) for
4 h, followed by three 5-min washes. The cells were sub-
sequently incubated with goat anti-rabbit (H ? L) FITC-
conjugated antibody. After washing with PBS, cells were
imaged using an image restoration microscope (Applied
Precision, USA).
Cell Viability/Cytotoxicity Assay
A Cytotoxicity Assay was Performed
Using a Cell Counting Kit-8 (Dojindo, Korea). SH-SY5Y
cells were plated in a 96-well plate at 5.0 9 104 in 100 lL
of RPMI 1640 medium containing 10 % FBS. After incu-
bation for 48 h, cells were treated with 0.5 lM or 2 lM
Tat-Hsp27 for 2 h. Subsequently, 10nM and 50nM okadaic
acid were added for 6 h to induce abnormally phosphory-
lated tau. Ten microliters of CCK-8 solution was added,
and the cells were incubated at 37 C for 2 h. The ab-
sorbance at 450 nm was measured using a microplate
reader (Molecular Devices Co., Menlo Park, CA).
In Situ Terminal Deoxynucleotidyl Transferase
dUTP Nick-End Labeling (TUNEL) Assay
SH-SY5Y cells were seeded on a 2-well slide at a density
of 5.0 9 105 per well, treated with 2 lM Tat-Hsp27 for
2 h, and then treated with 10 nM okadaic acid for 14 h. The
cells were fixed by immersion in PBS containing 4 %
formaldehyde (pH 7.4). After washing with PBS, the cells
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were permeabilized in 0.2 % Triton X-100 and washed
again. After treatment with equilibration buffer, the cells
were added to rTdT incubation buffer containing nu-
cleotide mix. To terminate the reaction, saline sodium ci-
trate buffer was added to the cells; nuclei were stained with
DAPI and the mounting media used was Vectashield. The
cells were analyzed under a fluorescence microscope at
520 nm (green fluorescence) and 460 nm (blue, DAPI).
Statistical Analysis
Statistical analysis was performed with the Statistical
Package for the Social Sciences (SPSS, IBM Corporation,
NY, USA). Statistical significance was determined by
analysis of variance (ANOVA) with Tukey’s HSD test and
student’s t test. All results are presented as the
mean ± standard deviation, and statistical significance was
considered at the 5 % level.
Results
The sequence encoding Tat-Hsp27 fusion protein was
cloned into the pET28a vector, which produces a recom-
binant protein with a hexahistidine tag (Fig. 1a) and puri-
fied using affinity purification and size exclusion
chromatography. Fractions containing His-tagged Tat-
Hsp27 were identified using 12 % SDS-PAGE analysis
with Coomassie Brilliant Blue staining. His-tagged Tat-
Hsp27 in fractions 1–6 exhibited high affinity for the
affinity matrix. The eluted His-tagged Tat-Hsp27 was fur-
ther purified using size exclusion chromatography. Frac-
tions containing His-tagged Tat-Hsp27 were identified
using 12 % SDS-PAGE with Coomassie Brilliant Blue
staining. His-tagged Tat-Hsp27 eluted as a single peak
from size exclusion chromatography, as confirmed by
Western blot analysis (Fig. 1d), and migrated to a position
slightly above the 25-kDa molecular weight marker in
12 % SDS-PAGE analysis. The purified recombinant His-
tagged wt-Hsp27 and Tat-Hsp27 was concentrated to 5.85
and 1.438 mg/mL as determined using the BCA assay,
respectively.
To investigate whether Tat-Hsp27 could be effectively
delivered into cells, we conjugated FITC to Tat-Hsp27.
Image restoration microscopy indicated that FITC-Tat-
Hsp27 was efficiently delivered into SH-SY5Y cells fol-
lowing treatment for 2 h at a concentration of 2 lM, in
contrast to 2 lM wt-Hsp27. We also performed Western
blot analysis to confirm the intracellular delivery of Tat-
Hsp27 and to determine whether its transduction is de-
pendent on the Tat-Hsp27 concentration. SH-SY5Y cells
were treated with Tat-Hsp27 for 2 h and were lysed using
RIPA buffer. As shown in Fig. 2b, Hsp27 was present in
the lysate of SH-SY5Y cells treated with 2 and 5 lM Tat-
Hsp27, whereas equivalent concentrations of wt-Hsp27 did
not transduce cells. Additionally, increasing the concen-
tration of Tat-Hsp27 used to treat cells resulted in an in-
creased level of delivered protein. Therefore, the
recombinant Tat-Hsp27 can be delivered into cells in a
concentration-dependent manner.
Because Hsp27 is known to have an effect on phos-
phorylation, we investigated whether Hsp27 can reduce the
level of hyperphosphorylated tau, which is implicated in
the pathogenesis of AD. SH-SY5Y cells were treated with
2 or 5 lM Tat-Hsp27 for 2 h, and the phosphorylation of
normal tau was induced by the addition of 50 or 100 nM
okadaic acid. To quantify the relative phosphorylation, we
normalized the level of hyperphosphorylated tau (p-tau) in
Western blot analysis to the level of total tau using Sig-
maPlot software. Following treatment with 50 or 100 nM
okadaic acid for 2 h, the level of hyperphosphorylated tau
was approximately 2.4-fold or three-fold greater than the
control group, respectively. Following treatment with
50 nM okadaic acid, the level of p-tau in cells pretreated
with 2 and 5 lM Tat-Hsp27 decreased with an increasing
concentration of Tat-Hsp27 (Fig. 3), whereas equivalent
concentration of tat peptide did not prevent tau hyper-
phosphorylation and oligomers (Supplementary Fig. S1).
Tat-Hsp27 did not revert tau phosphorylation and aggre-
gation into oligomers when added at the same time or after
okadaic acid (as data not shown). Following treatment with
100 nM okadaic acid, cells pretreated with 5 lM Tat-
Hsp27 showed slightly higher levels of p-tau than cells
pretreated with 2 lM Tat-Hsp27. This finding suggest that
when tau is hyperphosphorylated, the protective effect was
better 2 than 5 lM Tat-Hsp27 on the reduction in hyper-
phosphorylated tau. Therefore, we used 2 lM Tat-Hsp27 in
subsequent experiments. We also performed immunocy-
tochemistry using an anti-p-tau antibody conjugated to
FITC (Fig. 4). SH-SY5Y cells were treated with 2 lM Tat-
Hsp27 for 2 h and were subsequently treated with 10 nM
okadaic acid for 14 h. The level of p-tau was significantly
decreased compared with treatment with okadaic acid
alone (n = 3).
A cytotoxicity assay was performed to determine whe-
ther Tat-Hsp27 directly affected the cell death induced by
hyperphosphorylated tau. We first evaluated the relative
cell viability (RCV) in the presence of Tat-Hsp27 alone. As
shown in Fig. 5a, treatment with Tat-Hsp27 alone did not
alter the RCV of normal cells. In contrast, SH-SY5Y cells
treated with 10 and 50 nM okadaic acid for 6 h exhibited a
decrease in 70.45, 49.234 % cell viability (*p\ 0.05).
When cells were treated with 0.5 or 2 lM Tat-Hsp27 fol-
lowed by treatment with 10 and 50 nM okadaic acid, the
cell viability increased to 92.44, 90.78, 76.89, and
81.57 %, respectively (**p\ 0.01; Fig. 5b). Cells treated
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with 0.5 and 2 lM Tat-HSP27 clearly showed a protective
effect against cell death induced by hyperphosphorylated
tau. Treatment with 10 nM okadaic acid alone for 14 h
greatly increased the number of TUNEL-positive cells,
whereas the cells pretreated with 2 lM Tat-Hsp27 exhib-
ited decreased TUNEL positivity (Fig. 6). In the control
group, apoptotic cells comprised 2.29 % of the total
number of cells. Following exposure to 10 nM okadaic
Fig. 1 Purification of His-tagged Tat-Hsp27. a pET28a vector
containing hexahistidine (His6) and Tat protein transduction domain
and Hsp27 cDNA. b His-tagged Tat-Hsp27 was eluted from the
affinity chromatography column using isocratic elution buffer
(20 mM Tris–HCl, pH 7.5, 500 mM NaCl, and 1 M imidazole).
c His-tagged Tat-Hsp27 was further purified using size excluion
chromatography (20 mM Tris–HCl, pH 7.5, and 100 mM NaCl) and
eluted as a single peak. Fractions were analyzed using SDS-PAGE
after each purification step. d Western blot analysis of purified His-
tagged Tat-Hsp27 using anti-His tag, anti-Hsp27, and anti-Tat
antibodies
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acid, the percentage of apoptotic cells increased to
17.84 %. However, this increase was inhibited by
Tat-Hsp27 (4.56 %). Therefore, intracellular delivery of
Tat-Hsp27 prevented the apoptotic cell death induced by
hyperphosphorylated tau.
Discussion
In this study, the recombinant Tat-Hsp27 reduced the level
of hyperphosphorylated tau induced by okadaic acid in SH-
SY5Y neuroblastoma cells and prevented the apoptosis
induced by abnormal tau aggregates in our cellular model
of AD. The effect of Hsp27 on phosphorylated tau has
recently received increasing attention. However, few
studies have examined the therapeutic effect of Hsp27 on
hyperphosphorylated tau, which has been implicated in the
pathogenesis of AD. We demonstrate that Hsp27 exhibits a
protective effect on apoptotic cell death caused by patho-
logical tau. This finding suggests that Hsp27 may represent
a potential protein therapeutic for AD.
Tau stabilizes microtubules; however, tau mutations that
result in its hyperphosphorylation lead to the formation of
tau filaments that can form twisted ribbons or rope-like
filaments (Kosik and Shimura 2005). Using phosphoryla-
tion-dependent monoclonal antibodies against tau, mass
spectrometry, and sequencing, at least thirty phosphoryla-
tion sites have been reported (Bussie´re et al. 2000). Be-
cause the phosphorylation of tau is regulated by various
kinases, including proline-directed protein kinases and
Fig. 2 Transduction of
wt-Hsp27 and Tat-Hsp27 into
SH-SY5Y cells.
a Immunocytochemistry. FITC-
conjugated wt-Hsp27 or Tat-
Hsp27 was delivered into cells
and analyzed 2 h later. Image
restoration microscopy indicates
that Tat-Hsp27 was rapidly and
efficiently delivered, in contrast
to wt-Hsp27. Scale bar 30 lm.
b Protein from cell lysates of
SH-SY5Y cells treated with
wt-Hsp27 or Tat-Hsp27 was
analyzed using Western blot
analysis. The protein expression
was normalized to actin.
c Experimental design for
Tat-Hsp27 treatment in
SH-SY5Y cells
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glycogen synthase kinase 3, and phosphatases, including
Ser/Thr protein phosphatases 1, 2A, 2B (calcineurin) and
2C, we used okadaic acid, which is a protein phosphatase
inhibitor, to induce PHF-like hyperphosphorylation of tau
(Zhang and Simpkins 2010). Hsp27 facilitates the degra-
dation and prevents the aggregation of aberrant substrates
independent of ATP or ubiquitination (Jakob et al. 1993;
Shimura et al. 2004a, b). The mechanism by which Hsp27
prevents apoptosis could be from not only the interaction
between Hsp27 and the pathologically hyperphosphory-
lated tau but also from Hsp27-mediated inhibition of pro-
caspase-9 and caspase-3 (Concannon et al. 2003). PP2A
dephosphorylates Hsp27 more effectively than that of PP1,
which is weakly active. Many of the sites that are de-
phosphorylated by PP2A are phosphorylated by either
GSK-3b or Cdk5. These include S199, S202, T205, S396,
and S404 93-96. We used the AT8 antibody to detect
phosphorylated tau at Ser202 and Thr205 (Goedert et al.
1995). Okadaic acid inhibits Ser/Thr protein phosphatases
and can induce tau hyperphosphorylation and neurode-
generation (Kamat et al. 2013).
A recent study reported that hyperphosphorylation of tau
leads to a 20-fold inhibition of the tau–tubulin binding
affinity. This finding supports the critical role for tau in the
pathogenesis of NFT-induced degeneration because the
balance between kinases and phosphatases is disturbed in
AD, resulting in the disassociation of tau from micro-
tubules and its subsequent aggregation (Wischik et al.
2014). In our previous study, we showed that hyperphos-
phorylated tau, but not the overexpression of normal tau
alone, reduces the cell viability of the neuroblastoma cell
line SH-SY5Y (Ahn et al. 2013). Thus, in the present study,
a cellular model of AD was induced by the hyperphos-
phorylation of endogenous tau.
Moreover, we utilized the PTD of the HIV Tat protein to
enhance the delivery of Hsp27, thereby enhancing its
protective effect (Wadia and Dowdy 2005; Stetler et al.
2010). Conjugation with specific peptide sequences, which
are termed PTDs or cell-penetrating peptides, improves the
delivery of a range of agents, including antisense
oligonucleotides, plasmids, microbeads, and liposomes,
which suggests that these peptide sequences may represent
Fig. 3 Effect of Tat-Hsp27 on
tau hyperphosphorylation.
Western blot analysis of total
tau (HT 7) and p-tau(AT 8),
with b-actin as a loading
control. *p\ 0.05 compared
with the control. **p\ 0.05
compared with okadaic acid
alone. Values indicate
mean ± SD (Anova, Tukey’s
HSD test, n = 3 per group)
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a universal in vitro and in vivo cellular delivery system
(Green et al. 2003). We confirmed that the fusion protein of
Hsp27 and Tat PTD was delivered into normal human
neuroblastoma SH-SY5Y cells and into SH-SY5Y cells
containing hyperphosphorylated tau induced by okadaic
acid treatment. To determine whether Tat-Hsp27 has a
protective effect against okadaic acid-induced cell death,
SH-SY5Y cells containing hyperphosphorylated tau were
treated with the fusion protein. The levels of phosphory-
lated tau significantly decreased compared with the cells
that were not treated with Tat-Hsp27, and the relative cell
viability was enhanced. This result suggests that Tat-Hsp27
represents a potential protein therapeutic to reduce hyper-
phosphorylated tau.
Protein delivery systems offer several advantages, such
as the ease of production from synthetic or natural com-
pounds which provoke low inflammatory response (Rogers
and Rush 2012). Compared to other delivery systems, such
as gene delivery utilizing plasmids or viral vectors, our
recombinant Tat-Hsp27 has several advantages. The
straightforward purification of Tat-Hsp27 is amenable to
large-scale production. Moreover, Tat-Hsp27 is nontoxic
and stable and can be readily delivered into cells.
As previously mentioned, PTDs can readily and rapidly
deliver proteins into cells. Drugs to treat neurodegenerative
diseases must be capable of penetrating the blood–brain
barrier (BBB) to be effectively delivered (Ozsoy et al.
2009). However, greater than 98 % of all potential CNS
Fig. 4 Representative immunofluorescence images. a SH-SY5Y cells
were treated with 2 lM Tat-Hsp27 (2 h) followed by 10 nM okadaic
acid (14 h). All cells were fixed and stained with primary antibodies
against p-tau(AT 8) and the corresponding fluorescent secondary
antibody. Green (FITC) indicates phosphorylated tau. Scale bar
100 lm. b Quantitation of the immunofluorescence intensity demon-
strated that phosphorylated tau by Okadaic acid was decreased by
treatment with Tat-Hsp27. Values indicate mean ± SD (Anova,
Tukey’s HSD test, n = 3 per group). *p\ 0.05 compared with
okadaic acid alone
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drugs cannot cross the BBB (Brasnjevic et al. 2009).
Hence, we designed a recombinant Tat-Hsp27 fusion pro-
tein to treat a cellular AD model, and this fusion protein
was delivered into cells at high levels within 2 h (Fig. 2).
Therefore, we anticipate that the uptake of Tat-Hsp27 into
the brain will readily occur when nasally administered and
will protect against cell death caused by hyperphosphory-
lated tau, which is one of the primary causes of AD
Fig. 5 Cytotoxicity assay using the Cell Counting Kit-8. SH-SY5Y
cells were transduced with 0.5 or 2 lM Tat-Hsp27 alone (a) or prior
to treatment with 10 and 50 nM okadaic acid (b). The transduction of
Tat-Hsp27 alone does not affect the cell viability. *p\ 0.05
compared with the control. **p\ 0.01 compared with okadaic acid
alone. Values indicate mean ± SD (Anova, Tukey’s HSD test, n = 7
per group)
Fig. 6 Tat-Hsp27 inhibits apoptotic cell death induced by okadaic
acid. The TUNEL assay was performed to determine the extent of
programmed cell death. SH-SY5Y cells were treated with 10 nM
okadaic acid alone or following pretreatment with 2 lM Tat-Hsp27.
a Representative images of the TUNEL assay. Scale bar 100 lm.
b Quantitation of the percentage of TUNEL-positive cells indicated
that apoptosis induced by okadaic acid was decreased in cells
pretreated with Tat-Hsp27. Values indicate mean ± SD (Anova,
Tukey’s HSD test, n = 3 per group). *p\ 0.05
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(Brasnjevic et al. 2009; Schwarze et al. 1999). Our results
suggest that Tat-Hsp27 has a protective effect against hy-
perphosphorylated tau and could represent a valuable
protein therapeutic for AD.
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